albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-17. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
=== Post-war expansion of the Rowett Research Institute === When Boyd Orr returned to Aberdeen in early 1919, his plan for a larger Institute had still not been accepted. Indeed, even his plans for the annual maintenance grant had to be approved by the Professor of Agriculture in Cambridge, Thomas Barlow Wood. Despite gaining the latter's support, his expansion plans were at first rebuffed, although he succeeded in having the annual grant increased to £4,000. In 1920 he was introduced to John Quiller Rowett, a businessman who seemed to have qualms of conscience over the large profits he had made during the war. Shortly afterwards, the government agreed to finance half the cost of Boyd Orr's plan, provided he could raise the other half elsewhere. Rowett agreed to provide £10,000 for the first year, £10,000 for the second year, and gave an additional £2,000 for the purchase of a farm, provided that, "if any work done at the Institute on animal nutrition was found to have a bearing on human nutrition, the Institute would be allowed to follow up this work", a condition the Treasury was willing to accept. By September 1922 the buildings were nearly completed, and the renamed Rowett Research Institute was opened shortly thereafter by Queen Mary. Boyd Orr proved to be an effective fund-raiser from both government and private sources, expanding the experimental farm to around 1,000 acres (400 hectares), building a well-endowed library, and expanding the buildings.
Mitch McConnell, who led Trump's Republican Party in the Senate from 2007 to 2025, characterised attempts to seize Greenland as "trampling the sovereignty, respect, and trust of our allies" and that "the use of force ... would be an especially catastrophic act of strategic self-harm to America and its global influence". Republican senator Susan Collins and Speaker of the House of Representatives Mike Johnson called the threats and possible US military actions as "completely inappropriate". In mid-January, a delegation of US congresspeople from both major political parties, including senators Chris Coons, Lisa Murkowski, Jeanne Shaheen, and Thom Tillis, travelled to Copenhagen to meet with Danish and Greenlandic officials to underscore the value of their partnership. Former assistant secretary of state for arms control, verification, and compliance Frank A. Rose, the last US official to negotiate a defence agreement with Denmark, said Trump's behaviour threatened to undermine the access the United States had to the Danish territory, since, under the 1951 agreement, the US already had all the military access it needed.
== Occurrence == It is also produced by Cordyceps kyusyuensis (a close relative of C. militaris), but not by other insect pathogenic fungi such as C. bassiana, C. confragosa, C. takaomontana, Isaria fumosorosea, M. robertsii, and M. rileyi. Evidence for cordycepin in Ophiocordyceps sinensis (syn. Cordyceps sinensis) has been mixed, and its presence in this species was long considered controversial. More recent analyses using authenticated material and sensitive methods have detected low but measurable amounts: an HPLC–MS/MS study quantified cordycepin at 0.0076–0.029% (w/w) in authenticated wild material, a PLOS ONE comparison reported cordycepin in both cultivated and wild forms (higher on average in cultivated), and independent HPLC work found ~3 ppm in both wild and in‑vitro‑cultured O. sinensis mycelium. Overall, reported detection appears to be sample‑ and method‑dependent. It is also produced by Samsoniella hepiali (fungus identity confirmed by 18S rRNA) and Aspergillus nidulans Y176-2.
=== Variation among organisms === Organisms vary in their ability to take up foreign dsRNA and use it in the RNAi pathway. The effects of RNAi can be both systemic and heritable in plants and C. elegans, although not in Drosophila or mammals. In plants, RNAi is thought to propagate by the transfer of siRNAs between cells through plasmodesmata (channels in the cell walls that enable communication and transport). Heritability comes from methylation of promoters targeted by RNAi; the new methylation pattern is copied in each new generation of the cell. A broad general distinction between plants and animals lies in the targeting of endogenously produced miRNAs; in plants, miRNAs are usually perfectly or nearly perfectly complementary to their target genes and induce direct mRNA cleavage by RISC, while animals' miRNAs tend to be more divergent in sequence and induce translational repression. This translational effect may be produced by inhibiting the interactions of translation initiation factors with the mRNA's polyadenine tail. Some eukaryotic protozoa such as Leishmania major and Trypanosoma cruzi lack the RNAi pathway entirely. Most or all of the components are also missing in some fungi, most notably the model organism Saccharomyces cerevisiae. The presence of RNAi in other budding yeast species such as Saccharomyces castellii and Candida albicans, further demonstrates that inducing two RNAi-related proteins from S. castellii facilitates RNAi in S. cerevisiae.
Sources: en.wikipedia.org
Doug Ford is the 26th and current premier of Ontario (French: Premier ministre de l'Ontario), Canada. He won a majority in the 2018 Ontario general election, as leader of the Ontario Conservative Party caucus in the Legislative Assembly of Ontario and was sworn in as premier on June 29, 2018. He was re-elected with an increased majority in 2022, and again after calling a snap election for February 27, 2025.
Non-surgical rhinoplasty is a medical procedure in which injectable fillers, such as collagen or hyaluronic acid, are used to alter and shape a person's nose without invasive surgery. The procedure fills in depressed areas on the nose, lifting the angle of the tip or smoothing the appearance of bumps on the bridge. The procedure does not alter nose size, though it can be used to correct some functional birth defects. Originally developed at the turn of the twenty-first century, early attempts used biologically harmful soft-tissue fillers such as paraffin wax and silicone. After 2000, physicians use minimally invasive techniques using modern fillers.
== See also == Madrigal v. Quilligan No más bebés Sterilization law in the United States Eugenics in the United States Sterilization of Native American women Compulsory sterilization Anti-Mexican sentiment Chicano Movement Abortion rights movements East L.A. Walkouts Women's Rights
Sources: en.wikipedia.org
In two weeks' fighting, Hoepner's forces advanced 60 km (37 mi) (4 km (2.5 mi) per day). Lacking strength and mobility to conduct battles of encirclement, the Group undertook frontal assaults which proved increasingly costly. A lack of tanks, insufficient motor transport and a precarious supply situation, along with tenacious Red Army resistance and the air superiority achieved by Soviet fighters hampered the attack. The 3rd Panzer Group further north saw slightly better progress, averaging 6 km (3.7 mi) a day. The attack by the 2nd Panzer Group on Tula and Kashira, 125 km (78 mi) south of Moscow, achieved only fleeting and precarious success, while Guderian vacillated between despair and optimism, depending on the situation at the front. Facing pressure from the German High Command, Kluge finally committed his weaker south flank to the attack on 1 December. In the aftermath of the battle, Hoepner and Guderian blamed slow commitment of the south flank of the 4th Army to the attack for the German failure to reach Moscow, grossly overestimating the capabilities of Kluge's remaining forces, according to Stahel. It also failed to appreciate the reality that Moscow was a fortified position which the Wehrmacht lacked the strength to either encircle nor take in a frontal assault, again according to Stahel. In contrast Forczyk lays the blame in part on Kluge's disingenuous lack of commitment to the Moscow operation. As late as 2 December, Hoepner urged his troops forward stating that "the goal [the encirclement of Moscow] can still be achieved".
== Sex identification == The 2002 report on the grave had reported that "This is the only known Iron Age grave to contain both a sword and mirror, raising interesting questions as to the gender significance of both these grave goods", but that "preservation of bone and DNA was too poor to determine the person's sex". A 2016 paper said that "Their combined presence within the burial of a single individual represents a touchstone within the ongoing unraveling of a long-held, interconnected set of reified sex and gender assumptions that have permeated discussions of British Iron Age mortuary contexts" and that "Hillside Farm as a starting point highlights the need to keep in mind the potential significance of any aspect of the burial, not to deny that men and women may have existed, or that certain artifacts may have conveyed a gendered meaning, but to refrain from excluding other routes to identity, personhood, or significance before analysis begins." In 2023, American scientists used new techniques of analysis of dental peptides, which indicated that, with 96% probability, the person in the grave was female.
Federalism has a long tradition in German history. Until the early 19th century, the majority of the territory that later became Germany was part of the Holy Roman Empire, which in 1796 was made up of more than 300 individual political entities subject to the Holy Roman Emperor in Vienna. The number of states was greatly reduced during the Napoleonic Wars (1796–1814), and the Empire itself was abolished in 1806. The Congress of Vienna, which restructured Europe after the wars, created the highly federalized 39-state German Confederation in 1815. The Confederation was dissolved after the Austro-Prussian War (1866) in which Prussia defeated the Austrian Empire and effectively excluded it from taking part in the eventual unification of Germany. Following the war, the states of northern and central Germany united under the leadership of the Kingdom of Prussia to form the federal North German Confederation. During the Franco-Prussian War (1870–1871), the four southern German states of Bavaria, Württemberg, Baden and Hesse-Darmstadt joined the North German Confederation, which was rechristened the German Empire with Prussia's victory. The Reichstag and Federal Council (Bundesrat) gave the Prussian king the title of German Emperor (as of 1 January 1871). With only relatively minor changes that did not affect its federalized nature, the North German Constitution became the imperial constitution. The new German Empire included 25 states (three of them free cities) plus the imperial territory of Alsace–Lorraine, which had been won from France in the war.
== Screening == Because it can be difficult to measure weight-for-height Z scores (WHZ) frequently, screening is performed by physical exam, with careful examination of the child's feet to detect the presence of bilateral pitting edema. Screening for edema is essential for the diagnosis of kwashiorkor, since nearly two-thirds of kwashiorkor cases do not have evidence of acute wasting (i.e. mid-upper arm circumference (MUAC) < 125 mm, or WHZ < -2) when diagnosed with kwashiorkor.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.